Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$6.66 - $12.39 $5,834 - $10,853
-876 Reduced 0.49%
179,090 $1.35 Million
Q2 2022

Aug 15, 2022

SELL
$8.95 - $12.8 $160,822 - $230,003
-17,969 Reduced 9.08%
179,966 $1.81 Million
Q1 2022

May 16, 2022

BUY
$10.05 - $22.48 $26,652 - $59,616
2,652 Added 1.36%
197,935 $2.45 Million
Q4 2021

Feb 14, 2022

BUY
$17.78 - $33.08 $70,568 - $131,294
3,969 Added 2.07%
195,283 $4.47 Million
Q3 2021

Nov 15, 2021

BUY
$10.93 - $23.55 $8,186 - $17,638
749 Added 0.39%
191,314 $4.23 Million
Q2 2021

Aug 16, 2021

BUY
$10.0 - $14.52 $57,400 - $83,344
5,740 Added 3.11%
190,565 $2.47 Million
Q1 2021

May 17, 2021

BUY
$12.3 - $18.73 $56,272 - $85,689
4,575 Added 2.54%
184,825 $2.4 Million
Q4 2020

Feb 16, 2021

BUY
$12.94 - $16.05 $2.33 Million - $2.89 Million
180,250 New
180,250 $2.49 Million

Others Institutions Holding AUPH

About Aurinia Pharmaceuticals Inc.


  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.16B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Gilder Gagnon Howe & CO LLC Portfolio

Follow Gilder Gagnon Howe & CO LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.